Top

BMC Health Services Research

Published in:

Open Access 01-12-2018 | Research article

Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospital

Authors: Hongli Luo, Qingze Fan, Shunlin Xiao, Kun Chen

Published in: BMC Health Services Research | Issue 1/2018

Abstract

Background

Proton pump inhibitors (PPIs) remain one of the world’s most frequently prescribed medications and there is a growing number of publications on correct versus incorrect use of PPIs worldwide. The objective of this observational retrospective study was to assess changes in PPI prescribing trends over the past decade and pharmacists’ effect on optimizing PPI prescribing practice at a tertiary hospital in China.

Methods

We collected the prescriptions of PPIs in our hospital from January 2007 to December 2016. Then the rate of PPI prescribing, the defined daily doses (DDDs) and expenditures were calculated and plotted to show the change in utilization of and expenditure on PPIs. Reasons behind this change and effect of pharmacists’ intervention were evaluated by investigating the rationality of PPI use through sample surveys of patients of pre-intervention (Jul.-Dec. 2015) and post-intervention (Jul.-Dec. 2016).

Results

In outpatient settings, the rate of PPI prescribing remained almost constant, utilization (from 135,808 DDDs to 722,943 DDDs) and expenditure (from 1.85 million CNY to 7.96 million CNY) increased for the past ten years, dominated by oral formulations and rabeprazole. In contrast, in inpatient settings, the rate of PPI prescribing (from 20.41 to 37.21%), utilization (from 132,329 DDDs to 827,747 DDDs) and expenditure (from 3.15 million CNY to 25.29 million CNY) increased from 2007 to 2015 and then decreased, dominated by injection formulations and omeprazole. Pharmacist interventions could significantly promote the rational use of PPIs (44.00% versus 26.67%), decrease PPI use and reduce patients’ charges (P < 0.05).

Conclusions

The utilization of and expenditure on PPIs grew due to the increase of patients and irrational use of PPI. Pharmacist interventions help to reduce PPI utilization and expenditure and enhance rationality for inpatients, but much work should be done to regulate injection and originator formulas, and improve the rationality in the future.

Webster P. Antibiotic overprescribing a growing problem. CMAJ. 2017;189(5):E222. https://doi.org/10.1503/cmaj.1095383.CrossRefPubMedPubMedCentral

Kazberuk M, Brzosko S, Hryszko T, Naumnik B. Overuse of proton pump inhibitors and its consequences. Postepy Hig Med Dosw (Online). 2016;70(0):1112–6. https://doi.org/10.5604/17322693.1222106.CrossRef

Atik OS. Overuse and abuse of cortisone. Eklem Hastalik Cerrahisi. 2017;28(1):1. https://doi.org/10.5606/ehc.2017.00056.CrossRefPubMed

Guda NM, Noonan M, Kreiner MJ, Partington S, Vakil N. Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage? Am J Gastroenterol. 2004;99(7):1233–7. https://doi.org/10.1111/j.1572-0241.2004.30894.x.CrossRefPubMed

Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009. PLoS One. 2013;8(2):e56060. https://doi.org/10.1371/journal.pone.0056060.CrossRefPubMedPubMedCentral

Ramirez E, Lei SH, Borobia AM, Pinana E, Fudio S, Munoz R, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol. 2010;5(4):288–97.CrossRefPubMed

Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther. 2003;17(12):1503–6.CrossRefPubMed

Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28(4):189–93. https://doi.org/10.1007/s11096-006-9028-4.CrossRefPubMed

Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol. 2000;95(11):3118–22. https://doi.org/10.1111/j.1572-0241.2000.03259.x. PubMedCrossRef

10.

Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2–3. https://doi.org/10.1136/bmj.39406.449456.BE.CrossRefPubMedPubMedCentral

11.

Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012;28(6):615–20. https://doi.org/10.1097/MOG.0b013e328358d5b9.CrossRefPubMed

12.

LUO HL, XIAO SL, WEI QM. Investigation and analysis of the use of proton pump inhibitors in inpatients. Chinese J Drug Appl Monitor. 2015;12(06):372–5.

13.

XU ZL, LI YC, XIANG P. Investigate the use of PPI to stress ulcer prophylaxis in 1745 cases of surgical patients receiving aseptic-contaminative and contaminative incision operation. Chongqing. Medicine. 2014;43(24):3212–6.

14.

TANG JC. Investigation and analysis of clinical application of proton pump inhibitors in surgical patients of our hospital. China Med Herald. 2017;14(08):135–8.

15.

Eom CS, Lee SS. Risk of fracture and pneumonia from acid suppressive drugs. World J Methodol. 2011;1(1):15–21. https://doi.org/10.5662/wjm.v1.i1.15.CrossRefPubMedPubMedCentral

16.

Ho SW, Hsieh MJ, Yang SF, Yeh YT, Wang YH, Yeh CB. Risk of stroke-associated pneumonia with acid-suppressive drugs: a population-based cohort study. Medicine (Baltimore). 2015;94(29):e1227. https://doi.org/10.1097/MD.0000000000001227.CrossRef

17.

Chandra S, Agarwal D, Surana A. Risk of Clostridium difficile infection with acid-suppressive therapy; pitfalls in accurate estimation. Am J Gastroenterol. 2013;108(2):277–8. https://doi.org/10.1038/ajg.2012.394.CrossRefPubMed

18.

Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C, et al. Combination use of Clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2016; https://doi.org/10.1177/1074248416663647.

19.

Zhang HX, Li X, Huo HQ, Liang P, Zhang JP, Ge WH. Pharmacist interventions for prophylactic antibiotic use in urological inpatients undergoing clean or clean-contaminated operations in a Chinese hospital. PLoS One. 2014;9(2):e88971. https://doi.org/10.1371/journal.pone.0088971.CrossRefPubMedPubMedCentral

20.

Liu HH, Liao GP. The analysis of proton pump inhibitor use after clinical pharmacists intervention. China J Pharmaceut Econ. 2016;11(04):39–40. https://doi.org/10.12010/j.issn.1673-5846.2016.04.013.CrossRef

21.

Ye ZK, Liu Y, Cui XL, Liu LH. Critical appraisal of the quality of clinical practice guidelines for stress ulcer prophylaxis. PLoS One. 2016;11(5):e0155020. https://doi.org/10.1371/journal.pone.0155020.CrossRefPubMedPubMedCentral

22.

Luo H, Fan Q, Xiao S, Chen K. Impact of clinical pharmacist interventions on inappropriate prophylactic acid suppressant use in hepatobiliary surgical patients undergoing elective operations. PLoS One. 2017;12(10):e0186302. https://doi.org/10.1371/journal.pone.0186302.CrossRefPubMedPubMedCentral

23.

Luo HLYY, Wang SR, Xiao SL, Liu D. The analysis of prophylactic antibiotic use in perioperative period before and after antibiotic special campaign. Chongqing Med. 2012;41(32):3448–50. https://doi.org/10.3969/j.issn.1671-8348.2012.32.040. CrossRef

24.

Bez C, Perrottet N, Zingg T, Leung Ki EL, Demartines N, Pannatier A. Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department. J Eval Clin Pract. 2013;19(2):374–8. https://doi.org/10.1111/j.1365-2753.2012.01838.x.CrossRefPubMed

25.

Hwang KO, Kolarov S, Cheng L, Griffith RA. Stress ulcer prophylaxis for non-critically ill patients on a teaching service. J Eval Clin Pract. 2007;13(5):716–21. https://doi.org/10.1111/j.1365-2753.2006.00742.x.CrossRefPubMed

26.

Hussain S, Stefan M, Visintainer P, Rothberg M. Why do physicians prescribe stress ulcer prophylaxis to general medicine patients? South Med J. 2010;103(11):1103–10. https://doi.org/10.1097/SMJ.0b013e3181f6539d.CrossRefPubMed

27.

Koczka CP, Geraldino-Pardilla LB, Goodman AJ. Physicians’ opinions of stress ulcer prophylaxis: survey results from a large urban medical center. Dig Dis Sci. 2013;58(3):777–81. https://doi.org/10.1007/s10620-012-2423-x.CrossRefPubMed

28.

Ahn JS, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol. 2013;19(16):2560–8. https://doi.org/10.3748/wjg.v19.i16.2560.CrossRefPubMedPubMedCentral

29.

ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP commission on therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56(4):347–79.

30.

Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304–11. https://doi.org/10.1016/j.jacc.2011.12.024.CrossRefPubMed

31.

Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration. a systematic meta-analysis J Am Coll Cardiol. 2010;56(2):134–43. https://doi.org/10.1016/j.jacc.2009.12.071.CrossRefPubMed

32.

Zeng W, Finlayson AE, Shankar S, de Bruyn W, Godman B. Prescribing efficiency of proton pump inhibitors in China: influence and future directions. BMC Health Serv Res. 2015;15:11. https://doi.org/10.1186/s12913-014-0638-6.CrossRefPubMedPubMedCentral

33.

Tang Y, Zhang X, Yang C, Yang L, Wang H, Zhang X. Application of propensity scores to estimate the association between government subsidy and injection use in primary health care institutions in China. BMC Health Serv Res. 2013;13:183. https://doi.org/10.1186/1472-6963-13-183.CrossRefPubMedPubMedCentral

34.

Armstrong D. Intravenous proton pump inhibitor therapy: a rationale for use. Rev Gastroenterol Disord. 2005;5(Suppl 2):S18–30.PubMed

Title: Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospital
Authors: Hongli Luo
Qingze Fan
Shunlin Xiao
Kun Chen
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Health Services Research / Issue 1/2018
Electronic ISSN: 1472-6963
DOI: https://doi.org/10.1186/s12913-018-3358-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospital

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Vertical integrated service model: an educational intervention for chronic disease management and its effects in rural China – a study protocol

Drug overdose in the ED: a record linkage study examining emergency department ICD-10 coding practices in a cohort of people who inject drugs

Understanding the effectiveness and mechanisms of a social prescribing service: a mixed method analysis

Process, structural, and outcome quality indicators of nutritional care in nursing homes: a systematic review

Potential drug-drug interactions in outpatient department of a tertiary care hospital in Pakistan: a cross-sectional study

Integration of the work-related online aftercare intervention ‘GSA-online plus’ (healthy and without stress at the workplace) into clinical practice: study protocol for an implementation study